Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T06770
(Former ID: TTDS00325)
|
|||||
Target Name |
Human immunodeficiency virus Glycoprotein 41 (HIV gp41)
|
|||||
Synonyms |
Env polyprotein gp41 (33-511)
Click to Show/Hide
|
|||||
Gene Name |
HIV gp41
|
|||||
Target Type |
Successful target
|
[1] | ||||
Disease | [+] 1 Target-related Diseases | + | ||||
1 | Human immunodeficiency virus disease [ICD-11: 1C60-1C62] | |||||
Function |
Transmembrane protein gp41: Acts as a class I viral fusion protein. Under the current model, the protein has at least 3 conformational states: pre-fusion native state, pre-hairpin intermediate state, and post-fusion hairpin state. During fusion of viral and target intracellular membranes, the coiled coil regions (heptad repeats) assume a trimer-of-hairpins structure, positioning the fusion peptide in close proximity to the C- terminal region of the ectodomain. The formation of this structure appears to drive apposition and subsequent fusion of viral and target cell membranes. Complete fusion occurs in host cell endosomes and is dynamin-dependent, however some lipid transfer might occur at the plasma membrane. The virus undergoes clathrin- dependent internalization long before endosomal fusion, thus minimizing the surface exposure of conserved viral epitopes during fusion and reducing the efficacy of inhibitors targeting these epitopes. Membranes fusion leads to delivery of the nucleocapsid into the cytoplasm.
Click to Show/Hide
|
|||||
UniProt ID | ||||||
Sequence |
AVGIGALFLGFLGAAGSTMGAASMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVW
GIKQLQARILAVERYLKDQQLLGIWGCSGKLICTTAVPWNASWSNKSLEQIWNHTTWMEW DREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFNITNWLWYIKLFIMIVGG LVGLRIVFAVLSIVNRVRQGYSPLSFQTHLPTPRGPDRPEGIEEEGGERDRDRSIRLVNG SLALIWDDLRSLCLFSYHRLRDLLLIVTRIVELLGRRGWEALKYWWNLLQYWSQELKNSA VSLLNATAIAVAEGTDRVIEVVQGACRAIRHIPRRIRQGLERILL Click to Show/Hide
|
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Approved Drug(s) | [+] 1 Approved Drugs | + | ||||
1 | Enfuvirtide | Drug Info | Approved | Human immunodeficiency virus infection | [2] | |
Clinical Trial Drug(s) | [+] 7 Clinical Trial Drugs | + | ||||
1 | Sifuvirtide | Drug Info | Phase 3 | Human immunodeficiency virus infection | [3] | |
2 | ITV-1 | Drug Info | Phase 2 | Human immunodeficiency virus infection | [4] | |
3 | MaC46/M87o | Drug Info | Phase 1/2 | Human immunodeficiency virus-1 infection | [5] | |
4 | T-1249 | Drug Info | Phase 1/2 | Human immunodeficiency virus infection | [6] | |
5 | Combinectin | Drug Info | Phase 1 | Human immunodeficiency virus infection | [7] | |
6 | Gp41 HIV-1 vaccine | Drug Info | Phase 1 | Human immunodeficiency virus infection | [8] | |
7 | Multi-envelope HIV vaccine | Drug Info | Phase 1 | Human immunodeficiency virus infection | [9] | |
Mode of Action | [+] 2 Modes of Action | + | ||||
Modulator | [+] 4 Modulator drugs | + | ||||
1 | Enfuvirtide | Drug Info | [1] | |||
2 | Sifuvirtide | Drug Info | [10] | |||
3 | MaC46/M87o | Drug Info | [12] | |||
4 | Gp41 HIV-1 vaccine | Drug Info | [15] | |||
Inhibitor | [+] 2 Inhibitor drugs | + | ||||
1 | T-1249 | Drug Info | [13] | |||
2 | Combinectin | Drug Info | [14] |
Drug Binding Sites of Target | Top | |||||
---|---|---|---|---|---|---|
Ligand Name: [(1~{R})-1-azanyl-3-phenyl-propyl]-[(2~{S})-2-methanoyl-4-methyl-pentyl]phosphinic acid | Ligand Info | |||||
Structure Description | High-resolution crystal structure of ERAP1 in complex with 15mer phosphinic peptide | PDB:6RYF | ||||
Method | X-ray diffraction | Resolution | 1.72 Å | Mutation | No | [17] |
PDB Sequence |
RIQRAFVTI
|
|||||
|
||||||
Click to View More Binding Site Information of This Target with Different Ligands |
Chemical Structure based Activity Landscape of Target | Top |
---|---|
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | |||||
REF 2 | Combinations of the first and next generations of human immunodeficiency virus (HIV) fusion inhibitors exhibit a highly potent synergistic effect a... J Virol. 2009 Aug;83(16):7862-72. | |||||
REF 3 | The M-T hook structure increases the potency of HIV-1 fusion inhibitor sifuvirtide and overcomes drug resistance. J Antimicrob Chemother. 2014 Oct;69(10):2759-69. | |||||
REF 4 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036741) | |||||
REF 5 | Creating genetic resistance to HIV. Curr Opin Immunol. 2012 Oct;24(5):625-32. | |||||
REF 6 | ClinicalTrials.gov (NCT00048217) A Rollover Study to Provide Chronic T-1249 to Patients Who Completed Study T1249-102. U.S. National Institutes of Health. | |||||
REF 7 | ClinicalTrials.gov (NCT03984812) Evaluation of the Safety, Tolerability and Pharmacokinetics (PK) of GSK3732394 First-Time-in-Human (FTIH) Study. U.S. National Institutes of Health. | |||||
REF 8 | ClinicalTrials.gov (NCT01084343) Investigation of the Safety of an HIV-1 Vaccine Given Intra-muscularly and Intra-nasally to Healthy Female Subjects. U.S. National Institutes of Health. | |||||
REF 9 | ClinicalTrials.gov (NCT00187044) Evaluation of the Safety of a Polyvalent Virus in Healthy Adults. U.S. National Institutes of Health. | |||||
REF 10 | Broad antiviral activity and crystal structure of HIV-1 fusion inhibitor sifuvirtide.J Biol Chem.2012 Feb 24;287(9):6788-96. | |||||
REF 11 | Clinical pipeline report, company report or official report of Immunotech Laboratories. | |||||
REF 12 | DOI: 10.1038/mt.sj.6300124 | |||||
REF 13 | HIV entry inhibitors in clinical development. Curr Opin Pharmacol. 2002 Oct;2(5):523-8. | |||||
REF 14 | Clinical pipeline report, company report or official report of ViiV Healthcare. | |||||
REF 15 | Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine. PLoS One. 2010 Jan 25;5(1):e8617. | |||||
REF 16 | An assessment of the role of chimpanzees in AIDS vaccine research. Altern Lab Anim. 2008 Sep;36(4):381-428. | |||||
REF 17 | Mechanism for antigenic peptide selection by endoplasmic reticulum aminopeptidase 1. Proc Natl Acad Sci U S A. 2019 Dec 26;116(52):26709-26716. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.